TD Cowen Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steve Scala maintains a Hold rating on Bristol-Myers Squibb (NYSE:BMY) and raises the price target from $45 to $53.
August 12, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Steve Scala maintains a Hold rating on Bristol-Myers Squibb and raises the price target from $45 to $53.
The raised price target from $45 to $53 suggests a positive outlook for Bristol-Myers Squibb, which could lead to a short-term increase in stock price. However, the Hold rating indicates that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100